Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.50 |
| ▸ | ITGAV | P06756 | 20/20 | 0.50 |
| ▸ | ITGB6 | P18564 | 13/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.50 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.50 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.50 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.50 |
| ▸ | ITGA8 | P53708 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7836126 | 0.91 | ITGB3 (0.48) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL7836283 | 0.89 | ITGB3 (0.54) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL7823293 | 0.88 | ITGB3 (0.56) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6782965 | 0.86 | ITGB3 (0.63) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6773507 | 0.85 | ITGB3 (0.60) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6773624 | 0.85 | ITGB3 (0.66) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL7836124 | 0.80 | ITGB3 (0.52) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6773385 | 0.80 | ITGB3 (0.75) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL7823285 | 0.79 | ITGB3 (0.76) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6777155 | 0.78 | ITGB3 (0.48) | ITGB3ITGAVITGB6ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831199-B1 | In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 | G. D. SEARLE & CO. | 2004-12-14 | — | — | US | claimed |
| US-6831199-B1 | In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 | G. D. SEARLE & CO. | 2004-12-14 | — | — | US | disclosed |